LEN vs SOLV · rev $34.19B vs P/E 9.1, rev $8.25B
LEN (LEN) versus Solventum Corp. (SOLV) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Solventum Corp. (SOLV) is a medical instruments & supplies company listed on NYSE.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported SOLV revenue for 2024-12-31 was $8.25B. Net income was $479.0M. Revenue was up 0.7% from 2023-12-31 to 2024-12-31. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
LEN currently screens at market cap $0. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
Not investment advice. Open the LEN and SOLV stock pages for the full models.
Not investment advice.